Key Takeaways OPRX Q1 revenues rose 11% YoY to $21.9M, with 80% FY25 revenues already under contract. GDRX posted 2.6% YoY revenue growth to $203M, with higher revenue per user but declining MACs. OPRX's shift to subscriptions and DAAP expansion position it for stronger revenue momentum than GDRX.As healthcare continues its digital transformation, investors are eyeing platforms that promise to streamline access, reduce costs and drive smarter pharmaceutical engagement. OptimizeRx (OPRX) and GoodRx (GDRX) ...